Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

JOHNSON & JOHNSON

(JNJ)
  Report
Delayed Nyse  -  04:00 2022-12-07 pm EST
177.17 USD   +0.61%
04:31pJohnson & Johnson to Participate in the 41st Annual J.P. Morgan Healthcare Conference
BU
11:12aJohnson & Johnson : to Participate in the 41st Annual J.P. Morgan Healthcare Conference
PU
10:31aJohnson & Johnson - Tackling Health Disparities Through Empowerment, Partnership and Scholarship
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Johnson & Johnson Opens New R&D Facility in San Francisco Bay Area

09/20/2022 | 05:08am EST

By Will Feuer


Johnson & Johnson said it opened a nearly 200,000 square-foot research and development facility in the San Francisco Bay Area in a bid to increase collaboration with companies in the region.

The new facility will house up to 400 employees, more than doubling the R&D presence of Johnson & Johnson in the Bay Area, the company said Tuesday.

Research at the new site spans efforts to discover new treatments, RNA-based therapies, new approaches for infectious diseases, among other efforts, Johnson & Johnson said. It said co-locating its experts at the site will help expand its discovery pipeline.


Write to Will Feuer at Will.Feuer@wsj.com


(END) Dow Jones Newswires

09-20-22 0708ET

All news about JOHNSON & JOHNSON
04:31pJohnson & Johnson to Participate in the 41st Annual J.P. Morgan Healthcare Conference
BU
11:12aJohnson & Johnson : to Participate in the 41st Annual J.P. Morgan Healthcare Conference
PU
10:31aJohnson & Johnson - Tackling Health Disparities Through Empowerment, Partnership and Sc..
AQ
04:38aGSK, Pfizer, Sanofi Breathe Sigh Of Relief After US Court Tosses Lawsuits On Zantac Can..
MT
12/06Major Pharma Companies to Remain Defensive Through at least H1 2023 Amid M&As, New Prod..
MT
12/06Morgan Stanley Trims Price Target on Johnson & Johnson to $176 From $178, Maintains Equ..
MT
12/05Johnson & Johnson : Announcement for the purposes of Rule 2.8 of the Irish Takeover Panel ..
PU
12/05Yumanity Therapeutics to Pay Special Cash Dividend Related to Planned Asset Sale, Kinet..
MT
12/05Johnson & Johnson's Janssen Global Services Unit Says No Plans to Bid for Horizon Thera..
MT
12/03Johnson & Johnson : Announcement for the purposes of Rule 2.8 of the Irish Takeover Panel ..
PU
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Financials (USD)
Sales 2022 95 035 M - -
Net income 2022 20 677 M - -
Net cash 2022 10 806 M - -
P/E ratio 2022 21,8x
Yield 2022 2,45%
Capitalization 463 B 463 B -
EV / Sales 2022 4,76x
EV / Sales 2023 4,54x
Nbr of Employees 141 700
Free-Float 83,8%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 177,17 $
Average target price 181,81 $
Spread / Average Target 2,62%
EPS Revisions
Managers and Directors
Joaquin Duato Chief Executive Officer & Director
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Matthew Stuckley Senior Financial Analyst-Janssen Commercial Pharm
Alex Gorsky Executive Chairman
Peter Shen Global Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON3.57%460 411
ELI LILLY AND COMPANY33.42%350 179
ABBVIE INC.22.16%289 437
NOVO NORDISK A/S21.77%285 921
PFIZER, INC.-15.82%279 038
MERCK & CO., INC.43.65%276 181